Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 6/2022

07-04-2022 | Hypercholesterolemia | Cardiometabolic Disease and Treatment (R. Santos, Section Editor)

Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?

Authors: Rodrigo Alonso, Rosa Argüeso, Pilar Álvarez-Baños, Ovidio Muñiz-Grijalvo, Jose Luis Diaz-Diaz, Pedro Mata

Published in: Current Atherosclerosis Reports | Issue 6/2022

Login to get access

Abstract

Purpose of Review

Familial hypercholesterolemia is a high cardiovascular risk disorder. We will review the role of lipoprotein(a) in cardiovascular risk and in aortic valve stenosis in familial hypercholesterolemia, as well as its association with their phenotype, and strategies to identify this high-risk population.

Recent Findings

Patients with familial hypercholesterolemia have higher lipoprotein(a) levels mainly due to an increased frequency of LPA variants, and the cardiovascular risk is increased twofolds when both conditions coexist. Also, an increased risk for aortic valve stenosis and valve replacement has been observed with high lipoprotein(a) levels. Assessment of lipoprotein(a) during the cascade screening for familial hypercholesterolemia is a good opportunity to identify this high-risk population.

Summary

High cardiovascular risk in familial hypercholesterolemia is increased even more when lipoprotein(a) is also elevated. Measurement of lipoprotein(a) in these patients is crucial to identify those subjects who need to intensify LDL-cholesterol reduction pending availability of lipoprotein(a)-specific treatments.
Literature
1.
• Watts GF, Gidding S, Mata P, Pang J, Sullivan DR, Yamashita S, et al. Familial hypercholesterolemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol. 2020;17:360–77. (This publication summarizes recent advances in the knowledge of FH related to diagnosis, cardiovascular risk stratification, LDL-C targets, and management.)PubMedCrossRef
2.
Sijbrands EJ, Westendorp RG, Lombardi MP, Havekes LM, Frants RR, Kastelein JJ, et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolemia. Atherosclerosis. 2000;149:421–5.PubMedCrossRef
3.
Alonso R, Mata N, Castillo S, Fuentes F, Saenz P, Muñiz O, et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis. 2008;200:315–22.PubMedCrossRef
4.
Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolemia: screening of 98098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J. 2016;37:1384–94.PubMedCrossRef
5.
Perez de Isla L, Alonso R, Mata N, Saltijeral A, Muñiz O, Rubio-Marin P, et al. Coronary heart disease peripheral arterial disease, and stroke in familial hypercholesterolemia Insights from the SAFEHEART Registry. Arterioscler Thromb Vasc Biol. 2016;36:2004–10.PubMedCrossRef
6.
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–5853.PubMedPubMedCentralCrossRef
7.
Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, et al. SAFEHEART Investigators. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63:1982–9.PubMedCrossRef
8.
Vongpromek R, Bos S, Ten Kate GJ, Yahya R, Verhoeven AJ, de Feyter PJ, et al. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. J Intern Med. 2015;278:166–73.PubMedCrossRef
9.
•• Perez de Isla L, Watts GF, Alonso R, Díaz-Díaz JL, Muñiz-Grijalvo O, Zambón D, et al. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolemia. Eur Heart J. 2021;42:2201–11. (This study shows that aortic valve replacement due to AV stenosis is significantly increased in FH, and predictors are older age, history of ASCVD, hypertension, high lipoprotein(a) levels, and LDL-C adjusted Lp(a) burden.••)PubMedCrossRef
10.
Langsted A, Kamstrup P, Benn M, Tybjaerg-Hansen A, Nordestgaard B. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolemia: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4:577–87.PubMedCrossRef
11.
Mach F, Baigent C, Catapano A, Koskinas KC, Casula M, Badimón L, et al. 2019 ESC/EAS guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.PubMedCrossRef
12.
Slack J. Risks of ischaemic heart disease in familial hyperlipidemic states. Lancet. 1969;II:1380–2.CrossRef
13.
Hopkins P, Stephenson S, Wu L, Riley WA, Xin Y, Hunt SC. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2001;87:547–53.PubMedCrossRef
14.
Scientific Steering Committee on behalf of the Simon Broome Register Group. The risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 1991;303:893–6.CrossRef
15.
Duell PB, Gidding S, Andersen R, Knickelbine T, Anderson L, Gianos E, et al. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry. Atherosclerosis. 2019;289:85–93.PubMedCrossRef
16.
Khera A, Won HH, Peloso G, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67:2578–89.PubMedPubMedCentralCrossRef
17.
Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29:2625–33.PubMedPubMedCentralCrossRef
18.
Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.PubMedPubMedCentralCrossRef
19.
Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52–60.PubMedPubMedCentralCrossRef
20.
Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38:51–61.PubMedCrossRef
21.
Tsimikas S. A test in context: lipoprotein(a). Diagnosis, prognosis, controversies and emerging therapies. J Am Coll Cardiol. 2017;69:692–711.PubMedCrossRef
22.
Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA. 1989;86:4171–4.PubMedPubMedCentralCrossRef
23.
Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arteriosclerr Thromb Vasc Biol. 2000;20:522–8.CrossRef
24.
Li S, Wu NQ, Zhu CG, Zhang Y, Guo YL, Gao Y, et al. Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis. 2017;260:67–74.PubMedCrossRef
25.
Trinder M, DeCastro M, Azizi H, Cermakova L, Jackson LM, Frohlich J, et al. Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia. J Am Coll Cardiol. 2020;75:2682–93.PubMedCrossRef
26.
•• Ellis K, Perez de Isla L, Alonso R, Fuentes F, Watts G, Mata P. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. J Am Coll Cardiol. 2019;73:1029–39 (This study shows the feasibility and effectiveness of testing Lp(a) levels during FH cascade screening. Those FH patients with FH and high Lp. (This study shows the feasibility and effectiveness of testing Lp(a) levels during FH cascade screening. Those FH patients with FH and high Lp(a) levels have the highest risk of ASCVD compared to each disorder separately.••)PubMedCrossRef
27.
Kinpara K, Okada H, Yoneyama A, Okubo M, Murase T. Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. Clin Chim Acta. 2011;412:1783–7.PubMedCrossRef
28.
Saeedi R, Li M, Allard M, Frohlich J. Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol. Clin Biochem. 2014;47:1098–9.PubMedCrossRef
29.
Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256(6):482–90.PubMedCrossRef
30.
Nenseter M, Lindvig HW, Ueland T, Langslet G, Ose L, Holven KB, et al. Lipoprotein(a) levels in coronary heart disease-susceptible and-resistant patients with familial hypercholesterolemia. Atherosclerosis. 2011;216:426–32.PubMedCrossRef
31.
Watanabe J, Hamasaki M, Kotani K. Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review. Arch Med Sci Atheroscler Dis. 2020;5:e148–52.PubMedPubMedCentralCrossRef
32.
Pérez de Isla L, Alonso R, Mata N, Fernández-Pérez C, Muñiz O, Díaz-Díaz JL, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017;135:2133–44.PubMedCrossRef
33.
Paquette M, Bernard S, Cariou B, Hegele RA, Genest J, Trinder M, et al. Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2021;41:2632–40.PubMedCrossRef
34.
Pérez de Isla L, Watts GF, Muñiz-Grijalvo O, Díaz-Díaz JL, Alonso R, Zambón D, et al. A resilient type of familial hypercholesterolemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort. Eur J Prev Cardiol. 2021;2:zwab185. https://​doi.​org/​10.​1093/​eurjpc/​zwab185.CrossRef
35.
36.
Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol. 1997;29(3):630–4.PubMedCrossRef
37.
Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Investigators SEAS. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.PubMedCrossRef
38.
Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306–14.PubMedCrossRef
39.
Smith JG, Luk K, Schulz CA, Engert JC, Do R, Hindy G, et al. Association of low-density lipoprotein-cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA. 2014;312:1764–71.PubMedPubMedCentralCrossRef
40.
Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–12.PubMedPubMedCentralCrossRef
41.
Capoulade R, Chan KL, Yeang C, Mathieu P, Bossé Y, Dumesnil JG, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66:1236–46.PubMedCrossRef
42.
Mata P, Alonso R, Perez de Isla L, Badimón L. Dyslipidemia and aortic valve disease. Curr Opin Lipidol. 2021;32:349–54.PubMedCrossRef
43.
Alonso R, Díaz-Díaz JL, Arrieta F, Fuentes-Jiménez F, de Andrés R, Saenz P, et al. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: insights from SAFEHEART registry. J Clin Lipidol. 2016;10:953–61.PubMedCrossRef
44.
Alves AC, Alonso R, Díaz-Díaz JL, Medeiros AM, Jannes CE, Merchan A, et al. Phenotypical, clinical, and molecular aspects of adults and children with homozygous familial hypercholesterolemia in Iberoamerica. Arterioscler Thromb Vasc Biol. 2020;40:2508–15.PubMed
45.
Ten Kate GR, Bos S, Dedic A, Neefjes LA, Kurata A, Langendonk JG, et al. Increased aortic valve calcification in familial hypercholesterolemia: prevalence, extent, and associated risk factors. J Am Coll Cardiol. 2015;66:2687–95.PubMedCrossRef
46.
Mundal LJ, Hovland A, Igland J, Veierod MB, Holven KB, Bogsrud MP, et al. Association of low-density lipoprotein cholesterol with risk of aortic valve stenosis in familial hypercholesterolemia. JAMA Cardiol. 2019;4:1156–9.PubMedPubMedCentralCrossRef
47.
Perez de Isla L, Arroyo-Olivares R, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, et al. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. Rev Esp Cardiol. 2020;73:828–34.PubMedCrossRef
48.
Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, de Andrés R, Arroyo-Olivares R, et al. Efficacy of PCSK9 inhibitor in the treatment of heterozygous familial hypercholesterolemia: a clinical practice experience. J Clin Lipidol. 2021;15:584–92.PubMedCrossRef
49.
•• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244–55. (This RCS shows a dose-dependent reduction in Lp(a) levels ranging 35 to 80% using weekly subcutaneous infection of antisense oligonucleotide AKCEA-APO(a)-LRX. The most common adverse event was injection-site reactions.••)PubMedCrossRef
50.
Cao YX, Jin JL, Guo YL, Sun D, Liu HH, Wu NQ, et al. Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia. Atherosclerosis. 2019;291:27–33.PubMedCrossRef
Metadata
Title
Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?
Authors
Rodrigo Alonso
Rosa Argüeso
Pilar Álvarez-Baños
Ovidio Muñiz-Grijalvo
Jose Luis Diaz-Diaz
Pedro Mata
Publication date
07-04-2022
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 6/2022
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-022-01019-5

Other articles of this Issue 6/2022

Current Atherosclerosis Reports 6/2022 Go to the issue

Cardiometabolic Disease and Treatment (R. Santos, Section Editor)

Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies

Cardiometabolic Disease and Treatment (R. Santos, Section Editor)

Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia

Cardiometabolic Disease and Treatment (R. Santos, Section Editor)

Genetic and Mechanistic Insights into the Modulation of Circulating Lipoprotein (a) Concentration by Apolipoprotein E Isoforms

Cardiometabolic Disease and Treatment (R. Santos, Section Editor)

Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?

Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors)

DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm

Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors)

Next Generation Risk Markers in Preventive Cardio-oncology
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits